Cardiol Therapeutics Inc. (TSX:CRDL)

Market Cap	229.39M +87.5%
Revenue (ttm)	n/a
Net Income	-36.35M
EPS	-0.39
Shares Out	115.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,349
Open	1.990
Previous Close	1.990
Day's Range	1.930 - 2.035
52-Week Range	1.225 - 2.330
Beta	0.47
Analysts	Strong Buy
Price Target	6.00 (+195.57%)
Earnings Date	Aug 11, 2026

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol fo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Employees: 18
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: CRDL

Analyst Summary

According to 5 analysts, the average rating for CRDL stock is "Strong Buy." The 12-month stock price target is $6.00, which is an increase of 195.57% from the latest price.

Price Target

$6.00

(195.57% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 10, 2026

Data Sources Report a data error